shows that low-dose ATG can be successful in controlling severe acute GvHD in children and possibly avoiding chronic GvHD. However, infectious complications resulting from prolonged immunosuppression due to ATG are a major problem.
In five out of six patients, a therapeutic benefit was observed despite some delay in starting treatment. The pharmacological tolerance proved to be acceptable except in one patient (#3), who developed severe liver toxicity that resolved rapidly after ATG was stopped. None of the patients developed EBV-associated lymphoproliferative disorders.
Based on our experience, we feel that pediatric patients with severe acute GvHD may benefit from low-dose ATG. Opportunistic infections must be looked for carefully if ATG is used. 
